Business Wire

GN launches new technology platform to address the No.1 hearing aid challenge: hearing speech in noise

Share

GN Hearing, the global leader in hearing aid innovation, today announces the launch of ReSound OMNIA – a new hearing aid platform that will set a new standard in hearing technology and improve how people interact with the world around them. ReSound OMNIA provides significantly better hearing in noisy environments than any previous ReSound hearing aid. Coupled with optimal comfort and seamless connection to devices, these advances give people living with hearing loss a solution that will help them hear even the finest details of sound more easily.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005068/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GN launches new technology platform to address the No.1 hearing aid challenge: hearing speech in noise (Photo: Business Wire)

Despite advances in hearing aid technology over the last 10 years, hearing speech in noisy environments is still a challenge for people with hearing loss. In fact, 80% of people who wear hearing aids describe hearing in noise as a key challenge.1 To address this, ReSound OMNIA has been engineered to sound natural while still delivering 150% improvement in speech understanding compared to current hearing aids.2,* In a clinical study, 20% of respondents had issues with the sound of their own voice when wearing hearing aids.3 ReSound OMNIA also addresses this challenge by enhancing the user’s perception of ‘own voice’, so it sounds natural which contributes to higher satisfaction, leading to improved retention of hearing aids.

For additional sound performance and comfort, ReSound introduces Check My Fit, a new, first-of-its-kind feature in the ReSound Smart3D App. It gives users guidance to wear their hearing aids correctly via a quick ear selfie. Wearing hearing aids incorrectly can result in up to 11dB of sound escaping the ear, reducing the ability to hear considerably.4 Check My Fit also works with other ReSound hearing aids to help people enjoy sound fully without unnecessary trips to the audiologist.

At GN Hearing, we know that hearing in noise and hearing aid comfort are both critically important to hearing aid users”, says GN Hearing CEO, Gitte Aabo. “The new ReSound OMNIA hearing aids show what we can achieve when we put the needs of each individual user at the center of our design process. We address the difficult challenges such as speech understanding in noise so that they can enjoy every conversational nuance.”

Whether users choose to stream phone calls or music to their ears, they can connect naturally and hear it all with the highest quality through enhanced connectivity of ReSound OMNIA. Users can enjoy hands-free, crystal-clear phone calls at the touch of a button with iPhone and iPad**, and direct streaming from Android smartphones.

The new ReSound OMNIA hearing aids will be rolled out globally starting with the US and Canada on August 25, 2022, along with the equivalent Beltone Achieve line-up, in the popular Receiver-in-Ear (RIE) style. The ReSound OMNIA hearing aids are available in eight colors and in both rechargeable and non-rechargeable models. Also available from August 25, 2022, are GN Hearing’s recently launched Custom made by ReSound hearing aids in a Completely-in-Canal (CIC) style, to address more needs with a truly small fit, crafted for ease of use and all-day comfort.

Teleconference:

GN will host a teleconference at 15:30 (3.30 pm) CEST, August 16, 2022. Please visit www.gn.com/investor to access the teleconference. Presentation material will be available on the website approximately one hour prior to the teleconference.

For more information, visit the ReSound website.

* The 150% increase represents a 4.36db increase compared to legacy ReSound hearing aids.
** ReSound OMNIA hands-free calls are compatible with iPhone 11 or later, iPad Pro 12.9-inch (5th generation), iPad Pro 11-inch (3rd generation), iPad Air (4th generation), and iPad mini (6th generation) or later, with software updates iOS 15.3 and iPadOS 15.3 or later.

1MarkeTrak 10, 2019
2 Jespersen et al (2022)
3 Bennett et al (2020)
4 Yang et al (2022)

– ENDS –

NOTES TO EDITORS

About ReSound

ReSound is a recognised pioneer and innovator in hearing aids, which continues to set new standards to make life sound better for more people. Part of the GN Group, ReSound has unique access to cutting-edge competences from the audio world which enriches its medical-grade solutions with a deep understanding of user-centric design and lifestyle needs. By placing people at the center of innovation, ReSound consistently introduces game-changing experiences such as direct audio streaming from iPhone to hearing aids and remote care from hearing professionals via the user’s smartphone app. ReSound is a committed and trusted partner to leading hearing care professionals in over 100 countries around the world helping people hear more, do more and be more than they ever thought possible.

About GN Group

GN Group facilitates communication between people through its intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our innovation leadership, we leverage technological synergies to deliver unique and increasingly individualized user experiences in our products and solutions.

150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, audio, video and speech, wireless technologies, miniaturization, and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, SteelSeries, Jabra, Beltone, Interton, BlueParrott, Danavox and FalCom in around 100 countries. Founded in 1869, the GN Group employs 7,000 people and is listed on Nasdaq Copenhagen (GN.CO). ​

Visit our homepage GN.com and connect with us on LinkedIn and Facebook .

GN Store Nord A/S | Lautrupbjerg 7 | DK-2750 Ballerup | Denmark | +45 45 75 00 00 Co. Reg. no. 24257843 | info@gn.com | www.gn.com

© 2022 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad, and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:
Press and the media

Marie Schleimann Nordlund
Director of PR and Communication
Tel: +45 31 26 37 34

Steen Frentz Laursen
Vice President Corporate Communications
Tel: +45 45 75 07 21

Investors and analysts
Henriette Wennicke
Vice President, Investor Relations & Treasury
Tel: +45 45 75 03 33

Rune Sandager
Director, Investor Relations & Treasury
Tel: +45 45 75 92 57

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation ™28.9.2022 22:30:00 CEST | Press release

Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in the journal of the International Neuromodulation Society, Neuromodulation,further establish the efficacy and safety of ReActiv8 Restorative Neurostimulation, including compelling long-term durability and improvement over time on key outcome measures in the treatment of intractable chronic low back pain. The three-year data show improvements over results from the patients’ one-year and two-year visits on virtually all key efficacy measures. Of note: Outcome measure 1-year result (N = 176) 2-year result (N = 156) 3-year result (N = 133) Patients reporting pain intensity (Visual Analog Scale (VAS) score) reduced by 50% or more from baseline 64% 71% 77% Patients reporting a greater than 20-point reduction in Oswestry Disability Index 57% 61% 63% Patients reporting VAS score < 2.5 52% 65% 67% Patients taking opioids at basel

New Study From Egon Zehnder and Kearney Debunks the Myth of a Workplace Generational Divide28.9.2022 16:00:00 CEST | Press release

Egon Zehnder, the world’s preeminent leadership advisory firm, in partnership with Kearney, a leading global management consulting firm, today released findings from a new survey with over 8,000 respondents from eight different countries dismissing the myth of a generation divide in the workplace and showing that despite what is often believed, Gen Z, Millennials, Gen X and Boomers are more alike than different when it comes to workplace matters. The survey, titled “Different Generations, Same Ideals: What Workers of All Ages Value in their Jobs,” analyzed the similarities and differences among generations and found that they share more commonalities, especially when it comes to personal well-being, work-life balance, and desired traits from leadership. The most notable difference between the generations is how each group defines and plans to achieve their career desires. Key Findings from the survey include: Personal well-being, stability, and work-life balance matter more than money

BYD Announces Pre-sale Prices of European Passenger Car Range28.9.2022 15:35:00 CEST | Press release

BYD announces the pre-sale prices of its new European passenger car range. The world’s leading manufacturer of new energy vehicles and power batteries immediately introduces three full-electric passenger vehicles which will be delivered to Norway, Sweden, Denmark, the Netherlands, Belgium, Luxembourg and Germany. Before the end of the year customers in France and the United Kingdom will also have access to BYD’s zero-emission vehicles. After that, more dealers will be appointed supporting BYD’s plans to cover all major markets in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005587/en/ BYD Europe Product Premiere 2022 The pre-sale price for the BYD ATTO 3 is € 38,000. The BYD HAN and TANG pre-sale prices are € 72,000. These pre-sale prices apply to Germany as a reference for Europe and may differ from country to country. The three full-electric BYD vehicles are technologically advanced and well-suited to the e

Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany28.9.2022 15:27:00 CEST | Press release

Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany. The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy(*) such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services. Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros. (*) Targeted radioligand therapy is an innovative approach to cancer treatment that is considered to

Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations28.9.2022 15:00:00 CEST | Press release

Fore Biotherapeutics (Fore Bio), a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to FORE8934, its investigational, novel, small-molecule, orally available inhibitor for the treatment of patients with cancers harboring BRAF Class 1 (V600) and Class 2 (including fusions) alterations who have exhausted prior therapies. The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A drug that receives Fast Track designation may become eligible for Accelerated Approval, Priority Review, or Rolling Review if relevant criteria are met. “The FDA's Fast Track Designation for FORE8394 underscores the urgent need faced by patients with advanced BRAF-muted cancers who have no other options,” said Stacie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom